| C504897 | 12-(3-adamantan-1-ylureido)dodecanoic acid | 12-(3-adamantan-1-ylureido)dodecanoic acid results in decreased expression of BCL2L11 mRNA | 19435785 |
| C539551 | 1,2,4,5-benzenetetraamine | "1,2,4,5-benzenetetraamine results in increased cleavage of BCL2L11 protein" | 22276220 |
| C532162 | 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine | "[2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine co-treated with GDC-0973] results in decreased phosphorylation of BCL2L11 protein alternative form" | 22084396 |
| C532162 | 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine | "2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [GDC-0973 results in increased expression of BCL2L11 protein]" | 22084396 |
| C532162 | 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine | "2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [GDC-0973 results in increased expression of BCL2L11 protein alternative form]" | 22084396 |
| C532162 | 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine | "2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in increased expression of BCL2L11 mRNA" | 22084396 |
| C532162 | 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine | "2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in increased expression of BCL2L11 protein" | 23318440 |
| C532162 | 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine | "2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in increased expression of BCL2L11 protein alternative form" | 22084396 |
| C532162 | 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine | "BCL2L11 results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine" | 22084396 |
| C532162 | 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine | "GDC-0973 promotes the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in increased expression of BCL2L11 protein alternative form]" | 22084396 |
| C532162 | 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine | "[sorafenib co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] results in increased expression of BCL2L11 protein" | 23036488 |
| C511295 | 2,2',4,4'-tetrabromodiphenyl ether | "2,2',4,4'-tetrabromodiphenyl ether affects the expression of BCL2L11 mRNA" | 27589474 |
| C440850 | 2,4,3',5'-tetramethoxystilbene | "2,4,3',5'-tetramethoxystilbene results in increased expression of BCL2L11 protein" | 20490654 |
| C440850 | 2,4,3',5'-tetramethoxystilbene | "BCL2L11 protein results in increased susceptibility to 2,4,3',5'-tetramethoxystilbene" | 20490654 |
| C014024 | 2,4,5,2',4',5'-hexachlorobiphenyl | "2,4,5,2',4',5'-hexachlorobiphenyl promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of BCL2L11 mRNA]" | 21851831 |
| C561454 | 2,4-difluoro-N-(2-(methyloxy)-5-(4-(4-pyridazinyl)-6-quinolinyl)-3-pyridinyl)benzenesulfonamide | "[trametinib co-treated with 2,4-difluoro-N-(2-(methyloxy)-5-(4-(4-pyridazinyl)-6-quinolinyl)-3-pyridinyl)benzenesulfonamide] results in increased expression of BCL2L11 protein" | 22733540 |
| C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Doxorubicin] results in decreased phosphorylation of BCL2L11 protein | 20856197 |
| C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of BCL2L11 protein alternative form | 21179458 |
| C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | resveratrol promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of BCL2L11 protein alternative form] | 21179458 |
| C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [resveratrol inhibits the reaction [Glucose results in increased expression of BCL2L11 protein]] | 25471227 |
| C023035 | 3,4,5,3',4'-pentachlorobiphenyl | "3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of BCL2L11 mRNA" | 23196670 |
| C434003 | 3-(4-methylphenylsulfonyl)-2-propenenitrile | 3-(4-methylphenylsulfonyl)-2-propenenitrile results in increased expression of BCL2L11 protein | 20067466 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA" | 27188386 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA" | 27188386 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA" | 27188386 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA" | 27188386 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA" | 27188386 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA" | 27188386 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA" | 27188386 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA" | 27188386 |
| C027576 | 4-hydroxy-2-nonenal | 4-hydroxy-2-nonenal results in increased expression of BCL2L11 mRNA | 19191707 |
| C078956 | 4-methylthioamphetamine | 4-methylthioamphetamine results in increased expression of BCL2L11 mRNA | 23820845 |
| C078956 | 4-methylthioamphetamine | 4-methylthioamphetamine results in increased expression of BCL2L11 protein | 23820845 |
| C078956 | 4-methylthioamphetamine | "[N-Methyl-3,4-methylenedioxyamphetamine co-treated with Methamphetamine co-treated with 4-methylthioamphetamine co-treated with Dextroamphetamine] results in increased expression of BCL2L11 mRNA" | 23820845 |
| C078956 | 4-methylthioamphetamine | "[N-Methyl-3,4-methylenedioxyamphetamine co-treated with Methamphetamine co-treated with 4-methylthioamphetamine co-treated with Dextroamphetamine] results in increased expression of BCL2L11 protein" | 23820845 |
| C041594 | 4-nonylphenol | 4-nonylphenol results in increased expression of BCL2L11 protein | 26804764 |
| C012606 | 4-vinyl-1-cyclohexene dioxide | 4-vinyl-1-cyclohexene dioxide affects the expression of BCL2L11 mRNA | 20829426 |
| C034214 | 5-iodotubercidin | 5-iodotubercidin inhibits the reaction [acadesine results in increased expression of BCL2L11 mRNA] | 20664053 |
| C580598 | 5-OH-BDE-47 | 5-OH-BDE-47 results in decreased expression of BCL2L11 mRNA | 27589474 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA" | 27188386 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA" | 27188386 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA" | 27188386 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA" | 27188386 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA" | 27188386 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA" | 27188386 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA" | 27188386 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA" | 27188386 |
| C003001 | 7-ketocholesterol | 7-ketocholesterol affects the localization of BCL2L11 protein | 15955068 |
| C015929 | 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP | "8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of BCL2L11 protein" | 14996839 |
| C015929 | 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP | "BCL2L11 protein results in increased susceptibility to 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP" | 14996839 |
| C015929 | 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP | "8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of BCL2L11 mRNA" | 14996839 |
| C015929 | 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP | "8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of BCL2L11 protein" | 14996839 |
| C015929 | 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP | "BCL2L11 protein results in increased susceptibility to 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP" | 14996839 |
| C042834 | 9,10-anthraquinone | "9,10-anthraquinone analog results in increased expression of BCL2L11 protein" | 26915975 |
| C501332 | ABT-737 | ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein] | 17097560|1720071 |
| C501332 | ABT-737 | [ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]] promotes the reaction [BCL2L11 protein results in increased activity of BAX protein] | 17200714 |
| C501332 | ABT-737 | [BCL2L11 protein binds to BCL2 protein] which affects the susceptibility to ABT-737 | 17200714 |
| C501332 | ABT-737 | [MCL1 protein results in decreased activity of BCL2L11 protein] which results in decreased susceptibility to ABT-737 | 23341456 |
| C501332 | ABT-737 | BCL2L11 protein results in increased susceptibility to ABT-737 | 20038611 |
| C011651 | acadesine | 5-iodotubercidin inhibits the reaction [acadesine results in increased expression of BCL2L11 mRNA] | 20664053 |
| C011651 | acadesine | acadesine results in increased expression of BCL2L11 mRNA | 20664053 |
| C011651 | acadesine | acadesine results in increased expression of BCL2L11 protein | 20664053 |
| D000082 | Acetaminophen | Acetaminophen results in decreased expression of BCL2L11 mRNA | 26690555 |
| D000082 | Acetaminophen | Acetaminophen results in increased expression of BCL2L11 mRNA | 21420995|2570463 |
| D000082 | Acetaminophen | Acetaminophen affects the expression of BCL2L11 mRNA | 17562736 |
| D000082 | Acetaminophen | [Clofibrate co-treated with Acetaminophen] affects the expression of BCL2L11 mRNA | 17585979 |
| D000082 | Acetaminophen | PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of BCL2L11 mRNA] | 17585979 |
| D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein] | 15173094 |
| D016604 | Aflatoxin B1 | Aflatoxin B1 results in increased expression of BCL2L11 mRNA | 19770486 |
| D000393 | Air Pollutants | Air Pollutants analog results in decreased expression of BCL2L11 mRNA | 21757418 |
| C103303 | alitretinoin | alitretinoin results in increased expression of BCL2L11 protein | 16340750 |
| C103303 | alitretinoin | seocalcitol inhibits the reaction [alitretinoin results in increased expression of BCL2L11 protein] | 16340750 |
| D000535 | Aluminum | [APP protein modified form binds to Aluminum] which results in increased expression of BCL2L11 mRNA | 21298039 |
| D000638 | Amiodarone | Amiodarone results in increased expression of BCL2L11 mRNA | 19774075 |
| D000643 | Ammonium Chloride | Ammonium Chloride affects the expression of BCL2L11 mRNA | 16483693 |
| D003913 | Dextroamphetamine | Dextroamphetamine results in increased expression of BCL2L11 mRNA | 23820845 |
| D003913 | Dextroamphetamine | Dextroamphetamine results in increased expression of BCL2L11 protein | 23820845 |
| D003913 | Dextroamphetamine | "[N-Methyl-3,4-methylenedioxyamphetamine co-treated with Methamphetamine co-treated with 4-methylthioamphetamine co-treated with Dextroamphetamine] results in increased expression of BCL2L11 mRNA" | 23820845 |
| D003913 | Dextroamphetamine | "[N-Methyl-3,4-methylenedioxyamphetamine co-treated with Methamphetamine co-treated with 4-methylthioamphetamine co-treated with Dextroamphetamine] results in increased expression of BCL2L11 protein" | 23820845 |
| D018501 | Antirheumatic Agents | Antirheumatic Agents results in decreased expression of BCL2L11 mRNA | 24449571 |
| C006632 | arsenic trioxide | [arsenic trioxide co-treated with Curcumin] results in increased expression of BCL2L11 protein | 27430728 |
| C006632 | arsenic trioxide | arsenic trioxide inhibits the reaction [BCL2L11 protein binds to MCL1 protein] | 24956101 |
| C006632 | arsenic trioxide | arsenic trioxide promotes the reaction [matrine results in increased expression of BCL2L11 protein] | 23700110 |
| C006632 | arsenic trioxide | arsenic trioxide results in increased expression of BCL2L11 mRNA | 17530438 |
| C006632 | arsenic trioxide | arsenic trioxide results in increased expression of BCL2L11 protein | 17203211|2165518 |
| C006632 | arsenic trioxide | [arsenic trioxide results in increased expression of BCL2L11 protein] which results in decreased phosphorylation of AKT1 protein | 21655183 |
| C006632 | arsenic trioxide | BCL2L11 mutant form inhibits the reaction [arsenic trioxide results in increased cleavage of CASP3 protein] | 21655183 |
| C006632 | arsenic trioxide | BCL2L11 mutant form inhibits the reaction [arsenic trioxide results in increased cleavage of CASP9 protein] | 21655183 |
| C006632 | arsenic trioxide | matrine promotes the reaction [arsenic trioxide results in increased expression of BCL2L11 protein] | 23700110 |
| C006632 | arsenic trioxide | MMP9 protein inhibits the reaction [arsenic trioxide inhibits the reaction [BCL2L11 protein binds to MCL1 protein]] | 24956101 |
| C006632 | arsenic trioxide | MMP9 protein inhibits the reaction [arsenic trioxide results in increased expression of BCL2L11 protein] | 24956101 |
| D001194 | Asbestos | Asbestos results in decreased expression of BCL2L11 | 27042963 |
| D017638 | Asbestos, Crocidolite | "Asbestos, Crocidolite results in decreased expression of BCL2L11 mRNA" | 18687144 |
| D001241 | Aspirin | Aspirin results in increased expression of BCL2L11 mRNA | 19936928 |
| C406592 | azaspiracid | azaspiracid results in decreased expression of BCL2L11 mRNA | 28939011 |
| C517975 | AZD 6244 | AZD 6244 results in increased expression of BCL2L11 protein | 22729845 |
| C487081 | belinostat | belinostat results in increased expression of BCL2L11 protein | 18223231 |
| C006703 | benzo(b)fluoranthene | benzo(b)fluoranthene results in increased expression of BCL2L11 protein | 21392559 |
| D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in decreased expression of BCL2L11 mRNA | 26238291 |
| D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in increased expression of BCL2L11 mRNA | 15735009 |
| D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in decreased expression of BCL2L11 mRNA | 20713471 |
| D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in increased expression of BCL2L11 mRNA | 19770486|2171566 |
| D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in increased methylation of BCL2L11 gene | 28476633 |
| C072553 | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cisplatin results in increased phosphorylation of and results in increased degradation of BCL2L11 protein]] which results in increased susceptibility to Cisplatin | 21561860 |
| D001599 | Berberine | [Berberine co-treated with Niacinamide] results in increased expression of BCL2L11 mRNA | 26712469 |
| D001599 | Berberine | Berberine results in increased expression of BCL2L11 mRNA | 26712469 |
| D004958 | Estradiol | Estradiol affects the expression of BCL2L11 mRNA | 21826169 |
| D004958 | Estradiol | Estradiol results in increased expression of BCL2L11 mRNA | 23373633 |
| C006780 | bisphenol A | bisphenol A affects the expression of BCL2L11 mRNA | 21826169 |
| C006780 | bisphenol A | bisphenol A results in decreased expression of BCL2L11 mRNA | 22576693 |
| C006780 | bisphenol A | bisphenol A results in increased methylation of BCL2L11 gene | 22576693 |
| C006780 | bisphenol A | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BCL2L11 mRNA | 28628672 |
| C006780 | bisphenol A | bisphenol A results in increased expression of BCL2L11 protein | 24909818 |
| C006780 | bisphenol A | bisphenol A results in increased methylation of BCL2L11 promoter | 27312807 |
| C006780 | bisphenol A | bisphenol A affects the expression of BCL2L11 mRNA | 25181051 |
| C006780 | bisphenol A | bisphenol A results in increased methylation of BCL2L11 gene | 28505145 |
| C005961 | bis(tri-n-butyltin)oxide | bis(tri-n-butyltin)oxide results in increased expression of BCL2L11 mRNA | 22434021 |
| D000069286 | Bortezomib | Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein] | 15173094 |
| D000069286 | Bortezomib | BCL2L11 results in increased susceptibility to Bortezomib | 18566236 |
| D000069286 | Bortezomib | [Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein | 15173094 |
| D000069286 | Bortezomib | Bortezomib results in increased activity of BCL2L11 protein | 16446371 |
| D000069286 | Bortezomib | Bortezomib results in increased expression of BCL2L11 protein | 16024631|1732615 |
| C546611 | brevetoxin 2 | brevetoxin 2 results in increased expression of BCL2L11 mRNA | 20498034 |
| D015124 | 8-Bromo Cyclic Adenosine Monophosphate | [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of BCL2L11 protein | 16709600 |
| D019256 | Cadmium Chloride | Cadmium Chloride results in increased expression of BCL2L11 | 21787858 |
| D019256 | Cadmium Chloride | Cadmium Chloride results in increased expression of BCL2L11 protein | 28457857 |
| D002220 | Carbamazepine | Carbamazepine affects the expression of BCL2L11 mRNA | 24752500 |
| D012721 | Carbaryl | Carbaryl results in decreased expression of BCL2L11 mRNA | 27829164 |
| D002251 | Carbon Tetrachloride | Carbon Tetrachloride results in increased expression of BCL2L11 mRNA | 17482686 |
| D002251 | Carbon Tetrachloride | Carbon Tetrachloride results in increased expression of BCL2L11 protein | 17482686 |
| D002251 | Carbon Tetrachloride | PLG protein affects the reaction [Carbon Tetrachloride results in increased expression of BCL2L11 protein] | 17482686 |
| C469298 | CEP-11004 | CEP-11004 inhibits the reaction [sodium arsenite results in increased expression of BCL2L11 protein] | 16166651 |
| D020111 | Chlorodiphenyl (54% Chlorine) | Chlorodiphenyl (54% Chlorine) results in increased expression of BCL2L11 mRNA | 25270620 |
| D020245 | p-Chloromercuribenzoic Acid | "[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA" | 27188386 |
| D020245 | p-Chloromercuribenzoic Acid | p-Chloromercuribenzoic Acid results in decreased expression of BCL2L11 mRNA | 26272509 |
| C074702 | chromium hexavalent ion | chromium hexavalent ion results in increased expression of BCL2L11 mRNA | 17382205 |
| C074702 | chromium hexavalent ion | chromium hexavalent ion affects the expression of BCL2L11 mRNA | 28472532 |
| D002994 | Clofibrate | [Clofibrate co-treated with Acetaminophen] affects the expression of BCL2L11 mRNA | 17585979 |
| D002994 | Clofibrate | PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of BCL2L11 mRNA] | 17585979 |
| C018021 | cobaltous chloride | cobaltous chloride results in increased expression of BCL2L11 mRNA | 24386269 |
| D003042 | Cocaine | Cocaine results in increased expression of BCL2L11 mRNA | 16076954 |
| D003300 | Copper | [Copper deficiency co-treated with tetrathiomolybdate] results in increased cleavage of BCL2L11 protein | 22276220 |
| D003300 | Copper | [Copper deficiency co-treated with tetrathiomolybdate] results in increased expression of BCL2L11 protein | 22276220 |
| C551994 | crizotinib | BCL2L11 protein affects the reaction [crizotinib results in increased cleavage of CASP3 protein] | 22729845 |
| C551994 | crizotinib | BCL2L11 protein affects the susceptibility to crizotinib | 22729845 |
| C551994 | crizotinib | crizotinib results in increased expression of BCL2L11 protein | 22729845 |
| C551994 | crizotinib | MET gene mutant form promotes the reaction [crizotinib results in increased expression of BCL2L11 protein] | 22729845 |
| C551994 | crizotinib | crizotinib results in increased expression of BCL2L11 | 21716144 |
| D003471 | Cuprizone | Cuprizone results in increased expression of BCL2L11 mRNA | 25704630 |
| D003474 | Curcumin | [arsenic trioxide co-treated with Curcumin] results in increased expression of BCL2L11 protein | 27430728 |
| D003474 | Curcumin | Curcumin results in increased expression of BCL2L11 mRNA | 17332930 |
| C057862 | cyanoginosin LR | cyanoginosin LR results in increased expression of BCL2L11 mRNA | 17654400 |
| D003609 | Dactinomycin | Dactinomycin inhibits the reaction [sodium arsenite results in increased expression of BCL2L11 mRNA] | 16166651 |
| C531198 | dactolisib | dactolisib affects the expression of BCL2L11 protein | 25640480 |
| C515055 | darinaparsin | BCL2L11 protein affects the susceptibility to darinaparsin | 19417148 |
| C515055 | darinaparsin | darinaparsin results in increased expression of BCL2L11 mRNA | 19417148 |
| C014347 | decitabine | decitabine results in decreased methylation of BCL2L11 promoter | 19403302 |
| C014347 | decitabine | decitabine results in increased expression of BCL2L11 mRNA | 19403302 |
| C014347 | decitabine | decitabine results in increased expression of BCL2L11 protein | 19403302 |
| D003703 | Demecolcine | Demecolcine results in increased expression of BCL2L11 mRNA | 23649840 |
| D003907 | Dexamethasone | BCL2L11 protein results in increased susceptibility to Dexamethasone | 14996839 |
| D003907 | Dexamethasone | Dexamethasone results in increased expression of BCL2L11 mRNA | 12782123 |
| D003907 | Dexamethasone | Dexamethasone results in increased phosphorylation of BCL2L11 protein | 20067466 |
| D003907 | Dexamethasone | GSTM1 protein inhibits the reaction [Dexamethasone results in increased phosphorylation of BCL2L11 protein] | 20067466 |
| D003907 | Dexamethasone | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BCL2L11 mRNA | 28628672 |
| D003907 | Dexamethasone | NR3C1 protein affects the reaction [Dexamethasone results in increased expression of BCL2L11 protein] | 18515658 |
| D003907 | Dexamethasone | BCL2L11 protein results in increased susceptibility to Dexamethasone | 14996839 |
| D003907 | Dexamethasone | Dexamethasone results in increased expression of BCL2L11 mRNA alternative form | 17953376 |
| D003907 | Dexamethasone | Dexamethasone results in increased expression of BCL2L11 protein | 14996839 |
| C041517 | dibenzo(a,l)pyrene | "dibenzo(a,l)pyrene results in increased methylation of BCL2L11 gene" | 28476633 |
| D003993 | Dibutyl Phthalate | Dibutyl Phthalate results in decreased expression of BCL2L11 mRNA | 17361019|2126653 |
| D002945 | Cisplatin | [Cisplatin co-treated with jinfukang] results in increased expression of BCL2L11 mRNA | 27392435 |
| D002945 | Cisplatin | [Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of BCL2L11 protein | 21092744 |
| D002945 | Cisplatin | Cisplatin results in increased expression of BCL2L11 mRNA | 21092744|2739243 |
| D002945 | Cisplatin | Sirolimus promotes the reaction [Cisplatin results in increased expression of BCL2L11 mRNA] | 21092744 |
| D002945 | Cisplatin | [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cisplatin results in increased phosphorylation of and results in increased degradation of BCL2L11 protein]] which results in increased susceptibility to Cisplatin | 21561860 |
| D002945 | Cisplatin | Cisplatin results in increased phosphorylation of and results in increased degradation of BCL2L11 protein | 21561860 |
| D002945 | Cisplatin | [Cisplatin results in increased phosphorylation of and results in increased degradation of BCL2L11 protein] which results in decreased susceptibility to Cisplatin | 21561860 |
| D002945 | Cisplatin | MAPK1 mutant form inhibits the reaction [Cisplatin results in increased phosphorylation of and results in increased degradation of BCL2L11 protein] | 21561860 |
| D002945 | Cisplatin | MAPK3 mutant form inhibits the reaction [Cisplatin results in increased phosphorylation of and results in increased degradation of BCL2L11 protein] | 21561860 |
| D003633 | Dichlorodiphenyl Dichloroethylene | Dichlorodiphenyl Dichloroethylene affects the expression of BCL2L11 mRNA | 24576310 |
| D004008 | Diclofenac | Diclofenac affects the expression of BCL2L11 mRNA | 24752500 |
| C000944 | dicrotophos | dicrotophos results in increased expression of BCL2L11 mRNA | 28302478 |
| D004026 | Dieldrin | Dieldrin affects the expression of BCL2L11 mRNA | 22546817 |
| D004051 | Diethylhexyl Phthalate | Diethylhexyl Phthalate results in increased expression of BCL2L11 mRNA | 22610992 |
| D004052 | Diethylnitrosamine | Diethylnitrosamine results in increased expression of BCL2L11 mRNA | 24535843 |
| D002117 | Calcitriol | Calcitriol results in decreased expression of BCL2L11 mRNA | 12071473 |
| C010715 | di-n-octyl phthalate | di-n-octyl phthalate results in decreased expression of BCL2L11 protein | 29128616 |
| C051904 | dinophysistoxin 1 | dinophysistoxin 1 results in increased expression of BCL2L11 mRNA | 28939011 |
| D004178 | Diquat | Diquat results in increased expression of BCL2L11 mRNA | 26785375|2705728 |
| D004178 | Diquat | procyanidin B2 inhibits the reaction [Diquat results in increased expression of BCL2L11 mRNA] | 27057282 |
| C478085 | D-JNKI-1 | D-JNKI-1 inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of BCL2L11 protein] | 22427801 |
| C478085 | D-JNKI-1 | D-JNKI-1 inhibits the reaction [[Trinitrobenzenesulfonic Acid results in increased expression of MAPK9 protein] promotes the reaction [BCL2L11 protein binds to MAPK9 protein]] | 22427801 |
| C521792 | DMU-212 | DMU-212 affects the expression of BCL2L11 mRNA | 26428916 |
| C067311 | docetaxel | docetaxel results in increased degradation of BCL2L11 protein | 17317842 |
| C067311 | docetaxel | pyrazolanthrone inhibits the reaction [docetaxel results in increased degradation of BCL2L11 protein] | 17317842 |
| C067311 | docetaxel | U 0126 inhibits the reaction [docetaxel results in increased degradation of BCL2L11 protein] | 17317842 |
| D004317 | Doxorubicin | [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Doxorubicin] results in decreased phosphorylation of BCL2L11 protein | 20856197 |
| D004317 | Doxorubicin | BCL2L11 protein affects the susceptibility to [Doxorubicin co-treated with methylselenic acid] | 17339365 |
| D004317 | Doxorubicin | BCL2L11 protein affects the susceptibility to [Doxorubicin co-treated with Selenium] | 17339365 |
| D004317 | Doxorubicin | BCL2L11 protein promotes the reaction [[Doxorubicin co-treated with methylselenic acid] results in increased cleavage of and results in increased activity of CASP9 protein] | 17339365 |
| D004317 | Doxorubicin | BCL2L11 protein promotes the reaction [[Doxorubicin co-treated with methylselenic acid] results in increased degradation of PARP1 protein] | 17339365 |
| D004317 | Doxorubicin | BCL2L11 protein promotes the reaction [[Doxorubicin co-treated with Selenium] results in increased cleavage of and results in increased activity of CASP9 protein] | 17339365 |
| D004317 | Doxorubicin | BCL2L11 protein promotes the reaction [[Doxorubicin co-treated with Selenium] results in increased degradation of PARP1 protein] | 17339365 |
| D004317 | Doxorubicin | Doxorubicin results in decreased expression of BCL2L11 protein | 17339365 |
| D004317 | Doxorubicin | Doxorubicin results in increased expression of BCL2L11 protein | 25339540 |
| D004317 | Doxorubicin | [PI103 co-treated with Doxorubicin] results in decreased phosphorylation of BCL2L11 protein | 20856197 |
| D004317 | Doxorubicin | Doxorubicin results in increased expression of BCL2L11 protein | 26318906 |
| C098320 | efavirenz | BCL2L11 protein results in increased susceptibility to efavirenz metabolite | 21958719 |
| C098320 | efavirenz | efavirenz metabolite results in increased expression of BCL2L11 mRNA | 21958719 |
| C098320 | efavirenz | efavirenz metabolite results in increased expression of BCL2L11 protein | 21958719 |
| C098320 | efavirenz | efavirenz results in increased expression of BCL2L11 mRNA | 21958719 |
| C098320 | efavirenz | efavirenz results in increased expression of BCL2L11 protein | 21958719 |
| C100264 | enniatins | enniatins results in decreased expression of BCL2L11 mRNA | 27163883 |
| C118739 | entinostat | entinostat results in decreased expression of BCL2L11 mRNA | 26272509 |
| C118739 | entinostat | "[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA" | 27188386 |
| D000431 | Ethanol | [Ethanol co-treated with FOXO3 protein] results in increased expression of BCL2L11 mRNA | 26470730 |
| D000431 | Ethanol | Ethanol promotes the reaction [FOXO3 protein binds to BCL2L11 promoter] | 26470730 |
| D000431 | Ethanol | Ethanol promotes the reaction [FOXO3 protein modified form binds to BCL2L11 gene] | 26470730 |
| D000431 | Ethanol | [Ethanol results in increased phosphorylation of FOXO3 protein] promotes the reaction [FOXO3 protein modified form binds to BCL2L11 gene] | 26470730 |
| D000431 | Ethanol | Ethanol results in increased expression of BCL2L11 mRNA | 24095927 |
| D005020 | Ethyl Methanesulfonate | Ethyl Methanesulfonate results in increased expression of BCL2L11 mRNA | 23649840 |
| C000499 | ferric oxide | ferric oxide analog results in increased expression of BCL2L11 mRNA | 24525745 |
| C000499 | ferric oxide | ferric oxide analog results in increased expression of BCL2L11 protein | 25086211 |
| D005485 | Flutamide | CBL protein affects the reaction [Flutamide results in increased expression of BCL2L11 protein] | 16301331 |
| D005485 | Flutamide | Flutamide results in increased expression of BCL2L11 protein | 16301331 |
| D005485 | Flutamide | Flutamide results in increased expression of BCL2L11 mRNA | 24793618 |
| D005485 | Flutamide | Flutamide results in increased expression of BCL2L11 protein | 20850791 |
| C065180 | fluvastatin | [zoledronic acid co-treated with fluvastatin] results in increased expression of BCL2L11 mRNA | 16996129 |
| D005492 | Folic Acid | Folic Acid affects the expression of BCL2L11 mRNA | 16361273 |
| D005557 | Formaldehyde | Formaldehyde results in increased expression of BCL2L11 mRNA | 23649840 |
| C039281 | furan | furan results in increased expression of BCL2L11 mRNA | 20562052|2207923 |
| D005665 | Furosemide | Furosemide affects the expression of BCL2L11 mRNA | 17497460 |
| D005707 | Gallic Acid | Gallic Acid results in decreased expression of BCL2L11 mRNA | 29205955 |
| C546771 | gardiquimod | gardiquimod results in increased expression of BCL2L11 mRNA | 28003376 |
| C546771 | gardiquimod | Protein Kinase Inhibitors inhibits the reaction [gardiquimod results in increased expression of BCL2L11 mRNA] | 28003376 |
| C574276 | GDC-0973 | "[2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine co-treated with GDC-0973] results in decreased phosphorylation of BCL2L11 protein alternative form" | 22084396 |
| C574276 | GDC-0973 | "2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [GDC-0973 results in increased expression of BCL2L11 protein]" | 22084396 |
| C574276 | GDC-0973 | "2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [GDC-0973 results in increased expression of BCL2L11 protein alternative form]" | 22084396 |
| C574276 | GDC-0973 | "GDC-0973 promotes the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in increased expression of BCL2L11 protein alternative form]" | 22084396 |
| C574276 | GDC-0973 | GDC-0973 results in increased expression of BCL2L11 protein | 22084396 |
| C574276 | GDC-0973 | GDC-0973 results in increased expression of BCL2L11 protein alternative form | 22084396 |
| C574276 | GDC-0973 | BCL2L11 results in increased susceptibility to GDC-0973 | 22084396 |
| C574276 | GDC-0973 | GDC-0973 results in increased expression of BCL2L11 mRNA | 22084396 |
| C419708 | gefitinib | BCL2L11 protein results in increased susceptibility to gefitinib | 20237869 |
| C056507 | gemcitabine | gemcitabine results in increased expression of BCL2L11 mRNA | 17039268 |
| D005947 | Glucose | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [resveratrol inhibits the reaction [Glucose results in increased expression of BCL2L11 protein]] | 25471227 |
| D005947 | Glucose | Glucose results in increased expression of BCL2L11 protein | 25471227 |
| D005947 | Glucose | resveratrol inhibits the reaction [Glucose results in increased expression of BCL2L11 protein] | 25471227 |
| D006072 | Gossypol | Gossypol results in increased expression of BCL2L11 protein | 18840529 |
| D017313 | Fenretinide | Fenretinide results in increased expression of BCL2L11 mRNA | 28973697 |
| D006861 | Hydrogen Peroxide | Hydrogen Peroxide results in increased expression of BCL2L11 mRNA | 27057282 |
| D006861 | Hydrogen Peroxide | procyanidin B2 inhibits the reaction [Hydrogen Peroxide results in increased expression of BCL2L11 mRNA] | 27057282 |
| C559745 | hyperforin dicyclohexylammonium | hyperforin dicyclohexylammonium results in increased expression of BCL2L11 protein | 21376709 |
| C056599 | icariin | icariin inhibits the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased expression of BCL2L11 protein] | 25472572 |
| C056599 | icariin | icariin affects the expression of BCL2L11 protein | 25472572 |
| D000068877 | Imatinib Mesylate | BCL2L11 protein results in increased susceptibility to Imatinib Mesylate | 19403302 |
| D007213 | Indomethacin | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BCL2L11 mRNA | 28628672 |
| C572449 | INK128 | INK128 results in increased expression of BCL2L11 mRNA | 26536665 |
| C572449 | INK128 | INK128 results in increased expression of BCL2L11 protein | 26536665 |
| D015759 | Ionomycin | [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of BCL2L11 mRNA | 25613284 |
| D015056 | 1-Methyl-3-isobutylxanthine | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BCL2L11 mRNA | 28628672 |
| D007530 | Isoflurane | Isoflurane results in decreased expression of BCL2L11 mRNA | 16978161 |
| D007545 | Isoproterenol | Isoproterenol results in increased expression of BCL2L11 mRNA | 24286936 |
| D007545 | Isoproterenol | Isoproterenol results in increased expression of BCL2L11 protein | 14996839 |
| D007545 | Isoproterenol | Isoproterenol results in increased expression of BCL2L11 mRNA | 24286936 |
| C544151 | jinfukang | [Cisplatin co-treated with jinfukang] results in increased expression of BCL2L11 mRNA | 27392435 |
| C561695 | (+)-JQ1 compound | (+)-JQ1 compound affects the expression of BCL2L11 mRNA | 26397223 |
| C561695 | (+)-JQ1 compound | (+)-JQ1 compound promotes the reaction [panobinostat results in increased expression of BCL2L11 protein] | 24435446 |
| C561695 | (+)-JQ1 compound | (+)-JQ1 compound promotes the reaction [ponatinib results in increased expression of BCL2L11 protein] | 25053825 |
| C561695 | (+)-JQ1 compound | (+)-JQ1 compound promotes the reaction [quizartinib results in increased expression of BCL2L11 protein] | 25053825 |
| C561695 | (+)-JQ1 compound | (+)-JQ1 compound results in increased expression of BCL2L11 | 26575167 |
| C561695 | (+)-JQ1 compound | (+)-JQ1 compound results in increased expression of BCL2L11 mRNA | 24796395 |
| C561695 | (+)-JQ1 compound | (+)-JQ1 compound results in increased expression of BCL2L11 protein | 24435446|2505382 |
| C561695 | (+)-JQ1 compound | panobinostat promotes the reaction [(+)-JQ1 compound results in increased expression of BCL2L11 protein] | 24435446 |
| C561695 | (+)-JQ1 compound | PCI 32765 promotes the reaction [(+)-JQ1 compound results in increased expression of BCL2L11 protein] | 26254443 |
| C561695 | (+)-JQ1 compound | ponatinib promotes the reaction [(+)-JQ1 compound results in increased expression of BCL2L11 protein] | 25053825 |
| C561695 | (+)-JQ1 compound | quizartinib promotes the reaction [(+)-JQ1 compound results in increased expression of BCL2L11 protein] | 25053825 |
| C561695 | (+)-JQ1 compound | (+)-JQ1 compound affects the expression of BCL2L11 | 27406984 |
| C561695 | (+)-JQ1 compound | (+)-JQ1 compound results in increased expression of BCL2L11 protein | 25053825 |
| D007654 | Ketoconazole | Ketoconazole results in increased expression of BCL2L11 mRNA | 25808816 |
| C008261 | lead acetate | lead acetate results in increased expression of BCL2L11 mRNA | 21829687 |
| D008148 | Lovastatin | Lovastatin results in increased expression of BCL2L11 protein | 18766339 |
| D008148 | Lovastatin | pyrazolanthrone inhibits the reaction [Lovastatin results in increased expression of BCL2L11 protein] | 18766339 |
| D058185 | Magnetite Nanoparticles | [Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of BCL2L11 mRNA | 26378955 |
| D058185 | Magnetite Nanoparticles | [Succimer binds to Magnetite Nanoparticles] which results in increased expression of BCL2L11 mRNA | 21641980 |
| D058185 | Magnetite Nanoparticles | [Succimer co-treated with Magnetite Nanoparticles] results in increased expression of BCL2L11 mRNA | 26378955 |
| D008344 | Maneb | Maneb results in increased expression of BCL2L11 protein | 18266926 |
| D008344 | Maneb | [Paraquat co-treated with Maneb] results in increased expression of BCL2L11 protein | 18266926 |
| C025340 | manganese chloride | manganese chloride results in increased expression of BCL2L11 protein | 25732873 |
| C034244 | matrine | arsenic trioxide promotes the reaction [matrine results in increased expression of BCL2L11 protein] | 23700110 |
| C034244 | matrine | matrine promotes the reaction [arsenic trioxide results in increased expression of BCL2L11 protein] | 23700110 |
| C034244 | matrine | matrine results in increased expression of BCL2L11 protein | 23700110 |
| D017258 | Medroxyprogesterone Acetate | [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of BCL2L11 protein | 16709600 |
| C042720 | mercuric bromide | mercuric bromide results in decreased expression of BCL2L11 mRNA | 26272509 |
| C042720 | mercuric bromide | "[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA" | 27188386 |
| D008628 | Mercury | Mercury results in decreased expression of BCL2L11 mRNA | 19937285 |
| D008694 | Methamphetamine | Methamphetamine results in increased expression of BCL2L11 protein | 23820845 |
| D008694 | Methamphetamine | "[N-Methyl-3,4-methylenedioxyamphetamine co-treated with Methamphetamine co-treated with 4-methylthioamphetamine co-treated with Dextroamphetamine] results in increased expression of BCL2L11 mRNA" | 23820845 |
| D008694 | Methamphetamine | "[N-Methyl-3,4-methylenedioxyamphetamine co-treated with Methamphetamine co-treated with 4-methylthioamphetamine co-treated with Dextroamphetamine] results in increased expression of BCL2L11 protein" | 23820845 |
| C005219 | methyl cellosolve | methyl cellosolve results in increased expression of BCL2L11 mRNA | 19643169 |
| C004925 | methylmercuric chloride | methylmercuric chloride results in increased expression of BCL2L11 mRNA | 28001369 |
| D008741 | Methyl Methanesulfonate | Methyl Methanesulfonate results in increased expression of BCL2L11 mRNA | 23649840 |
| D018817 | N-Methyl-3,4-methylenedioxyamphetamine | "[N-Methyl-3,4-methylenedioxyamphetamine co-treated with Methamphetamine co-treated with 4-methylthioamphetamine co-treated with Dextroamphetamine] results in increased expression of BCL2L11 mRNA" | 23820845 |
| D018817 | N-Methyl-3,4-methylenedioxyamphetamine | "[N-Methyl-3,4-methylenedioxyamphetamine co-treated with Methamphetamine co-treated with 4-methylthioamphetamine co-treated with Dextroamphetamine] results in increased expression of BCL2L11 protein" | 23820845 |
| D018817 | N-Methyl-3,4-methylenedioxyamphetamine | "N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of BCL2L11 mRNA" | 23820845 |
| D018817 | N-Methyl-3,4-methylenedioxyamphetamine | "N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of BCL2L11 protein" | 23820845 |
| D008769 | Methylnitronitrosoguanidine | [Methylnitronitrosoguanidine co-treated with Sodium Chloride] results in decreased expression of BCL2L11 protein | 16030430 |
| D008769 | Methylnitronitrosoguanidine | S-allylcysteine inhibits the reaction [[Methylnitronitrosoguanidine co-treated with Sodium Chloride] results in decreased expression of BCL2L11 protein] | 16030430 |
| D015655 | 1-Methyl-4-phenylpyridinium | 1-Methyl-4-phenylpyridinium results in increased expression of BCL2L11 mRNA | 18266926 |
| C008493 | methylselenic acid | BCL2L11 protein affects the susceptibility to [Doxorubicin co-treated with methylselenic acid] | 17339365 |
| C008493 | methylselenic acid | BCL2L11 protein promotes the reaction [[Doxorubicin co-treated with methylselenic acid] results in increased cleavage of and results in increased activity of CASP9 protein] | 17339365 |
| C008493 | methylselenic acid | BCL2L11 protein promotes the reaction [[Doxorubicin co-treated with methylselenic acid] results in increased degradation of PARP1 protein] | 17339365 |
| C008493 | methylselenic acid | methylselenic acid results in increased cleavage of BCL2L11 protein | 18790785 |
| C008493 | methylselenic acid | methylselenic acid results in increased expression of BCL2L11 mRNA | 28161410 |
| C008493 | methylselenic acid | methylselenic acid results in increased expression of BCL2L11 protein | 17339365 |
| C008493 | methylselenic acid | Tamoxifen promotes the reaction [methylselenic acid results in increased cleavage of BCL2L11 protein] | 18790785 |
| C008542 | monodansylcadaverine | monodansylcadaverine results in increased expression of BCL2L11 protein | 16170020 |
| D009020 | Morphine | Morphine results in increased expression of BCL2L11 protein | 19292871 |
| D009151 | Mustard Gas | Mustard Gas results in increased expression of BCL2L11 mRNA | 18955075 |
| C583365 | N-(2-(1,1'-bicyclopropyl)-2-ylphenyl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide | "N-(2-(1,1'-bicyclopropyl)-2-ylphenyl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide results in increased expression of BCL2L11 mRNA" | 29244179 |
| C469937 | N(2)-(2-aminocyclohexyl)-N(6)-(3-chlorophenyl)-9-ethyl-9H-purine-2,6-diamine | "MYC mutant form inhibits the reaction [N(2)-(2-aminocyclohexyl)-N(6)-(3-chlorophenyl)-9-ethyl-9H-purine-2,6-diamine results in increased expression of BCL2L11 protein]" | 24444383 |
| C469937 | N(2)-(2-aminocyclohexyl)-N(6)-(3-chlorophenyl)-9-ethyl-9H-purine-2,6-diamine | "[N(2)-(2-aminocyclohexyl)-N(6)-(3-chlorophenyl)-9-ethyl-9H-purine-2,6-diamine co-treated with MYC protein] results in increased expression of BCL2L11 protein" | 24444383 |
| C469937 | N(2)-(2-aminocyclohexyl)-N(6)-(3-chlorophenyl)-9-ethyl-9H-purine-2,6-diamine | "N(2)-(2-aminocyclohexyl)-N(6)-(3-chlorophenyl)-9-ethyl-9H-purine-2,6-diamine results in increased expression of BCL2L11 protein" | 24444383 |
| D037742 | Nanotubes, Carbon | "Nanotubes, Carbon analog results in increased expression of BCL2L11 mRNA" | 25554681 |
| C017096 | n-butoxyethanol | n-butoxyethanol results in increased expression of BCL2L11 mRNA | 19812364 |
| D009532 | Nickel | Nickel affects the expression of BCL2L11 mRNA | 14575637 |
| D009532 | Nickel | trichostatin A inhibits the reaction [Nickel affects the expression of BCL2L11 mRNA] | 14575637 |
| C022838 | nickel chloride | nickel chloride affects the expression of BCL2L11 mRNA | 22110744 |
| C029938 | nickel sulfate | nickel sulfate results in increased expression of BCL2L11 mRNA | 17382205 |
| D015376 | Nimustine | BCL2L11 mutant form inhibits the reaction [Nimustine results in increased cleavage of CASP9 protein] | 26418950 |
| D015376 | Nimustine | Nimustine results in increased expression of BCL2L11 mRNA | 26418950 |
| D015376 | Nimustine | Nimustine results in increased expression of BCL2L11 protein | 26418950 |
| D015376 | Nimustine | pyrazolanthrone inhibits the reaction [Nimustine results in increased expression of BCL2L11 mRNA] | 26418950 |
| D019319 | Okadaic Acid | Okadaic Acid results in increased expression of BCL2L11 mRNA | 28939011 |
| C507134 | ON 01910 | ON 01910 results in increased expression of BCL2L11 | 21812421 |
| C016340 | o,p'-DDT | "o,p'-DDT analog results in decreased expression of BCL2L11 mRNA" | 22937105 |
| C016340 | o,p'-DDT | "o,p'-DDT analog results in increased expression of BCL2L11 mRNA" | 22937105 |
| C016340 | o,p'-DDT | "o,p'-DDT results in increased expression of BCL2L11 mRNA" | 22937105 |
| D008939 | Mitotane | Mitotane results in increased expression of BCL2L11 mRNA | 23485034 |
| D010100 | Oxygen | icariin inhibits the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased expression of BCL2L11 protein] | 25472572 |
| D010100 | Oxygen | Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased expression of BCL2L11 protein] | 25472572 |
| D010100 | Oxygen | [Oxygen co-treated with Oxygen deficiency] results in increased expression of BCL2L11 protein | 25472572 |
| D010100 | Oxygen | resveratrol inhibits the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased expression of BCL2L11 protein] | 25472572 |
| D010100 | Oxygen | SIRT1 mutant form promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased expression of BCL2L11 protein] | 25472572 |
| D017239 | Paclitaxel | BCL2L11 protein affects the susceptibility to Paclitaxel | 17652622 |
| C496932 | panobinostat | (+)-JQ1 compound promotes the reaction [panobinostat results in increased expression of BCL2L11 protein] | 24435446 |
| C496932 | panobinostat | "[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA" | 27188386 |
| C496932 | panobinostat | panobinostat promotes the reaction [(+)-JQ1 compound results in increased expression of BCL2L11 protein] | 24435446 |
| C496932 | panobinostat | panobinostat results in decreased expression of BCL2L11 mRNA | 26272509 |
| C496932 | panobinostat | panobinostat results in increased expression of BCL2L11 protein | 24435446 |
| D010269 | Paraquat | [Paraquat co-treated with Maneb] results in increased expression of BCL2L11 protein | 18266926 |
| D010269 | Paraquat | Paraquat results in decreased expression of BCL2L11 mRNA | 18836921 |
| D010269 | Paraquat | Paraquat results in increased expression of BCL2L11 protein | 18266926 |
| D010269 | Paraquat | FOXO3 mutant form inhibits the reaction [Paraquat results in increased expression of BCL2L11 mRNA] | 23620592 |
| D010269 | Paraquat | Paraquat results in increased expression of BCL2L11 mRNA | 23620592 |
| D010365 | Patulin | Patulin results in increased expression of BCL2L11 mRNA | 21844328 |
| C551803 | PCI 32765 | PCI 32765 promotes the reaction [(+)-JQ1 compound results in increased expression of BCL2L11 protein] | 26254443 |
| C539933 | pevonedistat | pevonedistat affects the expression of BCL2L11 mRNA | 24634471 |
| C539933 | pevonedistat | pevonedistat affects the expression of BCL2L11 protein | 24634471 |
| D010634 | Phenobarbital | Phenobarbital affects the expression of BCL2L11 mRNA | 23091169 |
| D010634 | Phenobarbital | Phenobarbital results in decreased expression of BCL2L11 mRNA | 19270015 |
| D010634 | Phenobarbital | Phenobarbital results in increased expression of BCL2L11 mRNA | 25270620 |
| D010662 | Phenylmercuric Acetate | "[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA" | 27188386 |
| D010662 | Phenylmercuric Acetate | Phenylmercuric Acetate results in decreased expression of BCL2L11 mRNA | 26272509 |
| C522973 | PI103 | [PI103 co-treated with Doxorubicin] results in decreased phosphorylation of BCL2L11 protein | 20856197 |
| C006253 | pirinixic acid | pirinixic acid results in increased expression of BCL2L11 mRNA | 12832660 |
| D059808 | Polyphenols | Polyphenols results in decreased expression of BCL2L11 mRNA | 16293270 |
| C545373 | ponatinib | (+)-JQ1 compound promotes the reaction [ponatinib results in increased expression of BCL2L11 protein] | 25053825 |
| C545373 | ponatinib | ponatinib promotes the reaction [(+)-JQ1 compound results in increased expression of BCL2L11 protein] | 25053825 |
| C545373 | ponatinib | ponatinib results in increased expression of BCL2L11 protein | 25053825 |
| C027373 | potassium chromate(VI) | potassium chromate(VI) results in increased expression of BCL2L11 mRNA | 17382205 |
| C432807 | pramanicin | BCL2L11 protein affects the susceptibility to pramanicin | 23441183 |
| C432807 | pramanicin | pramanicin analog results in increased expression of BCL2L11 protein | 23441183 |
| D044945 | Proanthocyanidins | Proanthocyanidins results in decreased expression of BCL2L11 mRNA | 29205955 |
| C045362 | prochloraz | prochloraz results in increased expression of BCL2L11 mRNA | 29038839 |
| C479580 | procyanidin B2 | procyanidin B2 inhibits the reaction [Diquat results in increased expression of BCL2L11 mRNA] | 27057282 |
| C479580 | procyanidin B2 | procyanidin B2 inhibits the reaction [Hydrogen Peroxide results in increased expression of BCL2L11 mRNA] | 27057282 |
| D047428 | Protein Kinase Inhibitors | Protein Kinase Inhibitors inhibits the reaction [gardiquimod results in increased expression of BCL2L11 mRNA] | 28003376 |
| C432165 | pyrazolanthrone | pyrazolanthrone inhibits the reaction [docetaxel results in increased degradation of BCL2L11 protein] | 17317842 |
| C432165 | pyrazolanthrone | pyrazolanthrone inhibits the reaction [Lovastatin results in increased expression of BCL2L11 protein] | 18766339 |
| C432165 | pyrazolanthrone | pyrazolanthrone inhibits the reaction [Nimustine results in increased expression of BCL2L11 mRNA] | 26418950 |
| C432165 | pyrazolanthrone | pyrazolanthrone inhibits the reaction [temozolomide results in increased expression of BCL2L11 mRNA] | 26418950 |
| C432165 | pyrazolanthrone | pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of BCL2L11 protein] | 16166651 |
| C031280 | pyrazole | pyrazole results in increased expression of BCL2L11 mRNA | 17945193 |
| C014175 | pyrazolo(3,4-d)pyrimidine | "pyrazolo(3,4-d)pyrimidine analog affects the expression of BCL2L11 mRNA" | 21152443 |
| D011794 | Quercetin | Quercetin results in decreased expression of BCL2L11 protein | 20438634 |
| D011794 | Quercetin | Quercetin results in increased expression of BCL2L11 protein | 25339540 |
| C544967 | quizartinib | (+)-JQ1 compound promotes the reaction [quizartinib results in increased expression of BCL2L11 protein] | 25053825 |
| C544967 | quizartinib | quizartinib promotes the reaction [(+)-JQ1 compound results in increased expression of BCL2L11 protein] | 25053825 |
| C544967 | quizartinib | quizartinib results in increased expression of BCL2L11 protein | 25053825 |
| D020849 | Raloxifene Hydrochloride | Raloxifene Hydrochloride results in increased expression of BCL2L11 mRNA | 19429434 |
| D017382 | Reactive Oxygen Species | [[[CD40LG protein co-treated with IL4 protein] results in increased abundance of Reactive Oxygen Species] which results in increased expression of and results in increased phosphorylation of and results in increased stability of TP53 protein] which results in decreased expression of BCL2L11 protein | 27634759 |
| D012116 | Resins, Plant | "Resins, Plant results in increased expression of BCL2L11 protein" | 27268964 |
| C059514 | resveratrol | BCL2L11 protein promotes the reaction [resveratrol results in increased activity of BAK1 protein] | 22245142 |
| C059514 | resveratrol | BCL2L11 protein results in increased susceptibility to resveratrol | 22245142 |
| C059514 | resveratrol | FOXO1 protein affects the reaction [resveratrol results in increased expression of BCL2L11 protein alternative form] | 21179458 |
| C059514 | resveratrol | FOXO3 protein affects the reaction [resveratrol results in increased expression of BCL2L11 protein alternative form] | 21179458 |
| C059514 | resveratrol | FOXO4 protein affects the reaction [resveratrol results in increased expression of BCL2L11 protein alternative form] | 21179458 |
| C059514 | resveratrol | resveratrol inhibits the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased expression of BCL2L11 protein] | 25472572 |
| C059514 | resveratrol | resveratrol promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of BCL2L11 protein alternative form] | 21179458 |
| C059514 | resveratrol | resveratrol results in increased expression of BCL2L11 protein | 17636462|2198039 |
| C059514 | resveratrol | resveratrol results in increased expression of BCL2L11 protein alternative form | 21179458 |
| C059514 | resveratrol | resveratrol results in increased expression of BCL2L11 protein | 20026400|2198039 |
| C059514 | resveratrol | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [resveratrol inhibits the reaction [Glucose results in increased expression of BCL2L11 protein]] | 25471227 |
| C059514 | resveratrol | resveratrol inhibits the reaction [Glucose results in increased expression of BCL2L11 protein] | 25471227 |
| C512984 | RO 3306 | MYC mutant form inhibits the reaction [RO 3306 results in increased expression of BCL2L11 protein] | 24444383 |
| C512984 | RO 3306 | [RO 3306 co-treated with MYC protein] results in increased expression of BCL2L11 protein | 24444383 |
| C512984 | RO 3306 | RO 3306 results in increased expression of BCL2L11 protein | 24444383 |
| C087123 | romidepsin | Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein] | 15173094 |
| C087123 | romidepsin | [Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein | 15173094 |
| C087123 | romidepsin | romidepsin results in increased expression of BCL2L11 protein | 15069698|1822323 |
| C065299 | S-allylcysteine | S-allylcysteine inhibits the reaction [[Methylnitronitrosoguanidine co-treated with Sodium Chloride] results in decreased expression of BCL2L11 protein] | 16030430 |
| C093642 | SB 203580 | SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of BCL2L11 protein] | 16818494 |
| D012643 | Selenium | BCL2L11 protein affects the susceptibility to [Doxorubicin co-treated with Selenium] | 17339365 |
| D012643 | Selenium | BCL2L11 protein promotes the reaction [[Doxorubicin co-treated with Selenium] results in increased cleavage of and results in increased activity of CASP9 protein] | 17339365 |
| D012643 | Selenium | BCL2L11 protein promotes the reaction [[Doxorubicin co-treated with Selenium] results in increased degradation of PARP1 protein] | 17339365 |
| D012643 | Selenium | Selenium results in increased expression of BCL2L11 protein | 17339365 |
| C002979 | selenomethylselenocysteine | selenomethylselenocysteine metabolite results in increased expression of BCL2L11 mRNA | 25321483 |
| C078903 | seocalcitol | seocalcitol inhibits the reaction [alitretinoin results in increased expression of BCL2L11 protein] | 16340750 |
| D017632 | Asbestos, Serpentine | "Asbestos, Serpentine results in decreased expression of BCL2L11 protein" | 19116364 |
| D017632 | Asbestos, Serpentine | "PRKD1 protein affects the reaction [Asbestos, Serpentine results in decreased expression of BCL2L11 protein]" | 19116364 |
| D017632 | Asbestos, Serpentine | "U 0126 promotes the reaction [Asbestos, Serpentine results in decreased expression of BCL2L11 protein]" | 19116364 |
| D012822 | Silicon Dioxide | Silicon Dioxide analog results in decreased expression of BCL2L11 mRNA | 25895662 |
| D012822 | Silicon Dioxide | Silicon Dioxide results in decreased expression of BCL2L11 mRNA | 25351596 |
| D012822 | Silicon Dioxide | Silicon Dioxide results in increased expression of BCL2L11 mRNA | 19073995 |
| D020123 | Sirolimus | [Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of BCL2L11 protein | 21092744 |
| D020123 | Sirolimus | Sirolimus promotes the reaction [Cisplatin results in increased expression of BCL2L11 mRNA] | 21092744 |
| D020123 | Sirolimus | Sirolimus results in increased expression of BCL2L11 protein | 21092744 |
| D020123 | Sirolimus | Sirolimus results in decreased expression of BCL2L11 protein | 18097008 |
| C017947 | sodium arsenite | CEP-11004 inhibits the reaction [sodium arsenite results in increased expression of BCL2L11 protein] | 16166651 |
| C017947 | sodium arsenite | Dactinomycin inhibits the reaction [sodium arsenite results in increased expression of BCL2L11 mRNA] | 16166651 |
| C017947 | sodium arsenite | pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of BCL2L11 protein] | 16166651 |
| C017947 | sodium arsenite | sodium arsenite results in decreased expression of BCL2L11 mRNA | 19822182 |
| C017947 | sodium arsenite | sodium arsenite results in increased expression of and affects the localization of BCL2L11 protein | 16166651 |
| C017947 | sodium arsenite | sodium arsenite results in increased expression of BCL2L11 mRNA | 16166651 |
| C017947 | sodium arsenite | BCL2L11 protein results in increased susceptibility to sodium arsenite | 16818494 |
| C017947 | sodium arsenite | SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of BCL2L11 protein] | 16818494 |
| C017947 | sodium arsenite | sodium arsenite promotes the reaction [MAPK14 protein results in increased phosphorylation of BCL2L11 protein] | 16818494 |
| C017947 | sodium arsenite | sodium arsenite results in increased expression of BCL2L11 protein alternative form | 20830294 |
| C017947 | sodium arsenite | sodium arsenite results in increased phosphorylation of BCL2L11 protein | 16818494 |
| C017947 | sodium arsenite | Taurine inhibits the reaction [sodium arsenite results in increased expression of BCL2L11 protein alternative form] | 20830294 |
| D012965 | Sodium Chloride | [Methylnitronitrosoguanidine co-treated with Sodium Chloride] results in decreased expression of BCL2L11 protein | 16030430 |
| D012965 | Sodium Chloride | S-allylcysteine inhibits the reaction [[Methylnitronitrosoguanidine co-treated with Sodium Chloride] results in decreased expression of BCL2L11 protein] | 16030430 |
| C471405 | sorafenib | sorafenib affects the localization of BCL2L11 protein | 18200035 |
| C471405 | sorafenib | "[sorafenib co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] results in increased expression of BCL2L11 protein" | 23036488 |
| C471405 | sorafenib | sorafenib results in decreased expression of BCL2L11 protein | 16109713 |
| C471405 | sorafenib | sorafenib results in increased expression of BCL2L11 protein | 18200035 |
| C525423 | SRT2183 | SRT2183 results in increased expression of BCL2L11 mRNA | 23681230 |
| D004113 | Succimer | [Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of BCL2L11 mRNA | 26378955 |
| D004113 | Succimer | [Succimer binds to Magnetite Nanoparticles] which results in increased expression of BCL2L11 mRNA | 21641980 |
| D004113 | Succimer | [Succimer co-treated with Magnetite Nanoparticles] results in increased expression of BCL2L11 mRNA | 26378955 |
| D013629 | Tamoxifen | Tamoxifen promotes the reaction [methylselenic acid results in increased cleavage of BCL2L11 protein] | 18790785 |
| D013654 | Taurine | Taurine inhibits the reaction [sodium arsenite results in increased expression of BCL2L11 protein alternative form] | 20830294 |
| C047246 | temozolomide | BCL2L11 mutant form inhibits the reaction [temozolomide results in increased cleavage of CASP9 protein] | 26418950 |
| C047246 | temozolomide | pyrazolanthrone inhibits the reaction [temozolomide results in increased expression of BCL2L11 mRNA] | 26418950 |
| C047246 | temozolomide | temozolomide results in increased expression of BCL2L11 mRNA | 26418950 |
| C047246 | temozolomide | temozolomide results in increased expression of BCL2L11 protein | 26418950 |
| D013739 | Testosterone | Testosterone deficiency results in increased expression of BCL2L11 protein | 20850791 |
| D013749 | Tetrachlorodibenzodioxin | "2,4,5,2',4',5'-hexachlorobiphenyl promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of BCL2L11 mRNA]" | 21851831 |
| D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin affects the expression of BCL2L11 mRNA | 21570461 |
| D013749 | Tetrachlorodibenzodioxin | [Tetrachlorodibenzodioxin co-treated with TIPARP gene mutant form] results in increased expression of BCL2L11 mRNA | 25975270 |
| D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in decreased expression of BCL2L11 mRNA | 19770486 |
| D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in increased expression of BCL2L11 mRNA | 15800033|2185183 |
| D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in increased expression of BCL2L11 mRNA | 19520675 |
| D013755 | Tetradecanoylphorbol Acetate | [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of BCL2L11 mRNA | 25613284 |
| C020809 | tetrathiomolybdate | [Copper deficiency co-treated with tetrathiomolybdate] results in increased cleavage of BCL2L11 protein | 22276220 |
| C020809 | tetrathiomolybdate | [Copper deficiency co-treated with tetrathiomolybdate] results in increased expression of BCL2L11 protein | 22276220 |
| D013853 | Thioacetamide | Thioacetamide results in increased expression of BCL2L11 mRNA | 23411599 |
| D014028 | Tobacco Smoke Pollution | Tobacco Smoke Pollution results in increased expression of BCL2L11 mRNA | 28065790 |
| D014028 | Tobacco Smoke Pollution | Tobacco Smoke Pollution results in increased expression of BCL2L11 mRNA | 28111298 |
| D014118 | Toxins, Biological | "Toxins, Biological affects the expression of BCL2L11 mRNA" | 19682533 |
| C560077 | trametinib | "[trametinib co-treated with 2,4-difluoro-N-(2-(methyloxy)-5-(4-(4-pyridazinyl)-6-quinolinyl)-3-pyridinyl)benzenesulfonamide] results in increased expression of BCL2L11 protein" | 22733540 |
| C560077 | trametinib | trametinib results in increased expression of BCL2L11 protein | 22733540 |
| D014212 | Tretinoin | Tretinoin results in decreased expression of BCL2L11 protein | 19176369 |
| C012589 | trichostatin A | "[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA" | 27188386 |
| C012589 | trichostatin A | trichostatin A inhibits the reaction [Nickel affects the expression of BCL2L11 mRNA] | 14575637 |
| C012589 | trichostatin A | trichostatin A results in decreased expression of BCL2L11 mRNA | 24935251|2627250 |
| C012589 | trichostatin A | trichostatin A results in increased expression of BCL2L11 mRNA | 24935251 |
| C015559 | trimellitic anhydride | trimellitic anhydride results in increased expression of BCL2L11 mRNA | 19042947 |
| D014302 | Trinitrobenzenesulfonic Acid | D-JNKI-1 inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of BCL2L11 protein] | 22427801 |
| D014302 | Trinitrobenzenesulfonic Acid | D-JNKI-1 inhibits the reaction [[Trinitrobenzenesulfonic Acid results in increased expression of MAPK9 protein] promotes the reaction [BCL2L11 protein binds to MAPK9 protein]] | 22427801 |
| D014302 | Trinitrobenzenesulfonic Acid | Trinitrobenzenesulfonic Acid results in increased expression of BCL2L11 protein | 22427801 |
| D014302 | Trinitrobenzenesulfonic Acid | [Trinitrobenzenesulfonic Acid results in increased expression of MAPK9 protein] promotes the reaction [BCL2L11 protein binds to MAPK9 protein] | 22427801 |
| C057693 | troglitazone | troglitazone results in decreased expression of BCL2L11 mRNA | 28973697 |
| C113580 | U 0126 | U 0126 inhibits the reaction [docetaxel results in increased degradation of BCL2L11 protein] | 17317842 |
| C113580 | U 0126 | "U 0126 promotes the reaction [Asbestos, Serpentine results in decreased expression of BCL2L11 protein]" | 19116364 |
| D014520 | Urethane | Urethane results in increased expression of BCL2L11 mRNA | 28818685 |
| D014635 | Valproic Acid | "[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA" | 27188386 |
| D014635 | Valproic Acid | Valproic Acid results in decreased expression of BCL2L11 mRNA | 23179753|2438349 |
| D014635 | Valproic Acid | Valproic Acid affects the expression of BCL2L11 mRNA | 17963808 |
| D014638 | Vanadates | Vanadates results in decreased expression of BCL2L11 mRNA | 22714537 |
| D001335 | Vehicle Emissions | Vehicle Emissions results in decreased methylation of BCL2L11 gene | 25560391 |
| C551177 | vemurafenib | [BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BCL2L11 protein | 27689874 |
| C551177 | vemurafenib | [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BCL2L11 protein] | 27689874 |
| C029297 | vinylidene chloride | vinylidene chloride results in increased expression of BCL2L11 mRNA | 26682919 |
| D009536 | Niacinamide | [Berberine co-treated with Niacinamide] results in increased expression of BCL2L11 mRNA | 26712469 |
| D009536 | Niacinamide | Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased expression of BCL2L11 protein] | 25472572 |
| D009536 | Niacinamide | Niacinamide results in increased expression of BCL2L11 mRNA | 26712469 |
| C111237 | vorinostat | "[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA" | 27188386 |
| C111237 | vorinostat | TNFSF10 protein promotes the reaction [vorinostat results in increased expression of BCL2L11 mRNA] | 19509267 |
| C111237 | vorinostat | TNFSF10 protein promotes the reaction [vorinostat results in increased expression of BCL2L11 protein] | 19509267 |
| C111237 | vorinostat | vorinostat results in increased expression of BCL2L11 mRNA | 19509267|2165254 |
| C111237 | vorinostat | vorinostat results in increased expression of BCL2L11 protein | 16144943|1950926 |
| C111237 | vorinostat | vorinostat results in increased expression of BCL2L11 protein alternative form | 17351739 |
| C111237 | vorinostat | vorinostat results in increased expression of BCL2L11 mRNA | 17331788 |
| C111237 | vorinostat | vorinostat results in increased expression of BCL2L11 protein | 17331788 |
| C009684 | withaferin A | withaferin A results in decreased expression of BCL2L11 protein | 20438634 |
| D015032 | Zinc | Zinc results in increased expression of BCL2L11 mRNA | 19071009 |
| C017803 | zinc protoporphyrin | zinc protoporphyrin results in increased expression of BCL2L11 protein | 27829220 |
| C088658 | zoledronic acid | [zoledronic acid co-treated with fluvastatin] results in increased expression of BCL2L11 mRNA | 16996129 |